🚨 Recent News in Myeloma Treatment! 🚨 The U.S. FDA has approved Blenrep (belantamab mafodotin-blmf) in combination with Velcade (bortezomib) and dexamethasone (BVd) for relapsed or refractory multiple myeloma. ✨ Based on the DREAMM-7 trial, this new treatment option showed a 51% lower risk of death and extended progression-free survival to 31.3 months compared to 10.4 months with standard care. This approval gives new hope to patients who have received at least two prior lines of therapy. 💪 📌 Learn more about this important advancement 👉 https://healthtree.org/myeloma/community/articles/blenrep-fda-approval?utm_source=social_media&utm_medium=meta&utm_campaign=socialmediaorganic&utm_content=general